# Research Idea Ranking

**Generated:** 2026-03-05T16:27:31.477246
**Models:** GPT-5.2, Gemini 3.1 Pro, Grok 4.1 Fast
**Reasoning:** high

## Comparison Table

| Idea | GPT-5.2 | Gemini 3.1 Pro | Grok 4.1 Fast |
|------|------|------|------|
| Right-to-Try Laws and the Market for Cli... | PURSUE (76) | — | PURSUE (82) |
| IVF Insurance Mandates and Women’s Caree... | PURSUE (64) | — | — |
| Nurse Practitioner Full Practice Authori... | CONSIDER (57) | — | CONSIDER (68) |
| State Conversion Therapy Bans and LGBTQ+... | SKIP (52) | — | SKIP (55) |
| State Indoor Tanning Bans for Minors and... | SKIP (38) | — | SKIP (48) |
| Idea 1: Right-to-Try Laws and the Market... | — | PURSUE (88) | — |
| Idea 3: IVF Insurance Mandates and Women... | — | CONSIDER (62) | — |
| Idea 2: Nurse Practitioner Full Practice... | — | SKIP (55) | — |
| Idea 5: State Conversion Therapy Bans an... | — | SKIP (42) | — |
| Idea 4: State Indoor Tanning Bans for Mi... | — | SKIP (32) | — |
| IVF Insurance Mandates and Women's Caree... | — | — | CONSIDER (62) |

---

## GPT-5.2

**Tokens:** 6647

### Rankings

**#1: Right-to-Try Laws and the Market for Clinical Trials**
- **Score: 76/100**
- **Strengths:** Very high novelty with “universe” administrative data and a clean, policy-relevant mechanism test (does an outside option for terminal patients disrupt trial supply/enrollment?). Strong built-in placebo structure (Phase I, observational studies, non-terminal conditions) makes it well-suited for an “opponent-killer” design.
- **Concerns:** The core risk is a weak/absent first stage: actual Right-to-Try utilization was tiny, so any detectable effects must operate through perceived regulatory risk or sponsor beliefs—harder to validate. State adoption may correlate with unobserved “biotech friendliness” trends that also shift trial siting, and trial “location” is a facility measure that may not map neatly to patient residence/enrollment.
- **Novelty Assessment:** Genuinely under-studied in economics; most existing work is legal/descriptive. Using ClinicalTrials.gov as the primary outcome universe for a state-policy DiD is also relatively uncommon.
- **Top-Journal Potential:** **Medium-High.** If you can show (i) a clear bite on enrollment speed/site selection in affected trial categories and (ii) a tight welfare argument about development delays, it can read as a belief-changing boundary test (“symbolic” laws can still distort innovation markets).
- **Identification Concerns:** Staggered adoption is credible, but you’ll need strong pre-trend/event-study diagnostics by trial type and perhaps region×time controls; also address anticipation (media debate before passage) and the 2018 federal act truncating the “never-treated” comparison.
- **Recommendation:** **PURSUE (conditional on: showing pre-trends are flat in the key trial categories; demonstrating a measurable first-stage proxy such as enrollment delays/completion hazards or sponsor/site reallocation rather than only counts; robustness to region-specific biotech trends and to dropping 2018Q1–2018Q2 / handling the federal law cleanly).**

---

**#2: IVF Insurance Mandates and Women’s Career Trajectories**
- **Score: 64/100**
- **Strengths:** The “career trajectories/human capital” angle is more novel than the well-trodden fertility/IVF-utilization focus, and it connects to a first-order question (gender wage gap via delayed fertility). Good scope for heterogeneity/placebos (men; older women; small-firm workers potentially exempt; mandate stringency).
- **Concerns:** The ACS window (2005–2024) is a major limitation because many mandates are pre-2005—so identification relies disproportionately on later adopters and mandate expansions, shrinking effective variation. Treated status is mismeasured (only some women are actually covered, depending on employer size, self-insurance ERISA exemptions, plan type), which can attenuate effects and complicate interpretation.
- **Novelty Assessment:** Moderately novel: IVF mandates have a literature, but labor-market/career impacts are much less developed than fertility outcomes; still, you must clearly differentiate from prior “mandates → labor supply” or “mandates → fertility timing” work.
- **Top-Journal Potential:** **Medium.** Could reach a top field journal if it credibly establishes a causal chain (mandate → delayed first birth → higher wages/experience accumulation) with convincing timing and heterogeneity; top-5 odds depend on delivering a sharp, surprising mechanism rather than a modest wage effect.
- **Identification Concerns:** Policy adoption likely correlates with broader, slow-moving gender/family-policy trends; parallel trends may be tenuous without richer controls or alternative designs (e.g., border-county comparisons, mandate-exposure by firm size/insurance type, or using expansions/IVF-specific provisions as the main treatment).
- **Recommendation:** **CONSIDER (upgrade to PURSUE if you can: anchor identification on post-2005 discrete expansions/IVF-specific tightening; measure exposure better—e.g., via firm size/industry insurance rates; and build a tight fertility-timing first stage using Vital Statistics).**

---

**#3: Nurse Practitioner Full Practice Authority and Rural Mortality**
- **Score: 57/100**
- **Strengths:** High policy relevance and a plausible causal chain (FPA → NP supply/access in shortage areas → mortality). Data are feasible and long-run panels exist, allowing serious pre-trend testing and dynamic effects.
- **Concerns:** Novelty is limited: NP scope-of-practice has been studied extensively across access, utilization, and some health outcomes; mortality specifically is a high bar and can be noisy/slow-moving at county-year frequency. Adoption is likely endogenous to access problems and political climate, which are themselves correlated with mortality trends.
- **Novelty Assessment:** Low-to-moderate; the specific rural mortality framing helps, but reviewers will view it as part of a crowded SOP/FPA literature unless the design or mechanism evidence is unusually strong.
- **Top-Journal Potential:** **Low-Medium.** A top field journal is possible if you deliver compelling mechanism evidence (provider entry, visit rates, avoidable mortality) and a design that convincingly isolates rural effects; top-5 is unlikely given saturation unless the results overturn a strong prior.
- **Identification Concerns:** Staggered DiD with long horizons helps, but you’ll need more than state-year DiD—e.g., border discontinuities, dose-response using pre-existing NP training capacity, or strong first-stage shifts in rural primary care availability that precede mortality changes.
- **Recommendation:** **CONSIDER (but only if paired with a sharper design than vanilla staggered DiD—border-county/event-study plus strong first-stage on access and “avoidable” mortality categories).**

---

**#4: State Conversion Therapy Bans and LGBTQ+ Youth Mental Health**
- **Score: 52/100**
- **Strengths:** High-stakes policy question with clear welfare relevance, and the within-state comparison (LGBTQ+ vs non-LGBTQ+ youth) is an intuitive starting point. If credible, even null results could matter.
- **Concerns:** The treated group is effectively “youth exposed to conversion therapy providers,” which is likely small and hard to observe; many observed mental-health changes would more plausibly reflect broader stigma/political climate shifts correlated with adoption. YRBSS sexual identity coverage is patchy and biennial, producing a short, unbalanced panel with limited power and compositional noise.
- **Novelty Assessment:** Moderate: there is likely some public health quasi-experimental work, but rigorous economics-style causal evaluation is not common; however, novelty won’t compensate for weak measurement/identification.
- **Top-Journal Potential:** **Low-Medium.** It could become publishable if you can convincingly separate “ban” effects from contemporaneous pro-LGBTQ policy bundles and secular trends; absent that, top outlets will view it as hopelessly confounded.
- **Identification Concerns:** Staggered adoption is heavily policy-clustered; triple-diff (LGBTQ status × state × time) does not solve endogeneity if LGBTQ identification/reporting and mental health are themselves affected by evolving climate and survey participation.
- **Recommendation:** **SKIP (unless you can secure better data: e.g., administrative claims/encounters, provider discipline data, or a design exploiting sharp enforcement changes rather than broad ban adoption).**

---

**#5: State Indoor Tanning Bans for Minors and the Tanning Industry**
- **Score: 38/100**
- **Strengths:** Clear regulated behavior and a potentially clean “ban → youth behavior → industry contraction” narrative. Some appealing placebos (adult outcomes; other personal-care sectors).
- **Concerns:** The main economic outcome is poorly measured: NAICS 812199 is not tanning-specific, so signal-to-noise may be too low for credible inference. Health outcomes (melanoma incidence) have long lags and confounding changes in screening/diagnosis; YRBSS state coverage gaps further weaken the panel and power.
- **Novelty Assessment:** Moderate—less studied in economics—but the data/measurement limitations dominate.
- **Top-Journal Potential:** **Low.** Even with clean DiD, it risks reading as “competent but not exciting,” and measurement problems will invite skepticism.
- **Identification Concerns:** Few treated states (especially for outright bans) plus noisy treatment/outcome mapping makes staggered DiD fragile; any null would be uninterpretable without strong power and a demonstrable first stage in youth tanning.
- **Recommendation:** **SKIP (unless you can obtain tanning-salon-specific licensing data or scanner/transactions data that directly measure tanning activity and firm exit).**

---

### Summary

This is a solid batch with one standout: **Right-to-Try and clinical trials** has the best combination of novelty, data scale, and a legible mechanism that could matter for innovation policy. **IVF mandates and careers** is the next-best if you can redesign around post-2005 policy variation and sharpen exposure measurement; the others are either too saturated (NP FPA) or too data/identification constrained (conversion therapy bans; tanning bans).

---

## Gemini 3.1 Pro

**Tokens:** 8186

Here is my evaluation of the research proposals, ranked from most to least promising. As requested, I have applied a highly critical lens, grounding my assessments in empirically observed editorial preferences for top economics journals.

### Rankings

**#1: Idea 1: Right-to-Try Laws and the Market for Clinical Trials**
- **Score**: 88/100
- **Strengths**: This proposal perfectly executes the "winning arc" for top journals: it leverages "universe" administrative data to test a highly debated but causally unstudied policy, and it maps a clear causal chain from a shock to a concrete welfare margin (drug development delays). The inclusion of built-in placebos (Phase I, observational, non-terminal) provides the exact kind of "opponent-killer" diagnostics that referees demand.
- **Concerns**: The primary risk is an underpowered null if the pharmaceutical industry simply ignored the state laws entirely, though the proposal smartly anticipates this by framing a powered null as a policy-relevant bound on "derailing clinical trials."
- **Novelty Assessment**: Extremely high. While legal and bioethics scholars have debated Right-to-Try extensively, there is zero causal economics literature on its market effects. 
- **Top-Journal Potential**: High. A top-5 or top field journal (like *AEJ: Policy*) would find this exciting because it tests whether symbolic legislation has real, unintended market consequences (the substitution/offset channel). The use of the ClinicalTrials.gov API as a novel dataset adds significant scientific content.
- **Identification Concerns**: The staggered DiD design is clean, but the authors must ensure that the 9 "never-treated" states are a valid counterfactual and not fundamentally different in their baseline clinical trial infrastructure.
- **Recommendation**: PURSUE

**#2: Idea 3: IVF Insurance Mandates and Women's Career Trajectories**
- **Score**: 62/100
- **Strengths**: Pivoting from the heavily studied fertility effects of IVF mandates to the labor market/gender wage gap implications is a smart, policy-relevant reframing. It addresses a first-order question about the trade-offs between biological clocks and peak career earning years.
- **Concerns**: There is a fatal mismatch in the proposed data timeline: the ACS panel starts in 2005, but the earliest adopters passed mandates in 1987. You cannot test pre-trends or capture the treatment effect for the most mature cohorts with this data window.
- **Novelty Assessment**: Medium. IVF mandates are a well-worn topic in health/demographic economics (e.g., Schmidt 2007, Abramowitz 2014), but the specific focus on career trajectory and the gender wage gap offers a fresh, valuable angle.
- **Top-Journal Potential**: Medium. It has potential for a solid field journal (e.g., *JHR* or *AEJ: Applied*), but to hit a top-5, it would need to cleanly resolve the data timing issue and likely incorporate a structural or lifecycle model to endogenize the career/fertility trade-off.
- **Identification Concerns**: The "data window starts after implementation" flaw for early adopters is a known killer in peer review. The authors must use Decennial Census (1980-2000) or CPS data to capture the pre-periods for early adopting states.
- **Recommendation**: CONSIDER (conditional on: replacing/supplementing ACS data with historical CPS/Census data to capture pre-1987 baseline trends).

**#3: Idea 2: Nurse Practitioner Full Practice Authority and Rural Mortality**
- **Score**: 55/100
- **Strengths**: The proposal benefits from a very long horizon (30+ years) and a large number of treated cohorts, which allows for the estimation of long-run dynamic effects. 
- **Concerns**: Mortality is an incredibly distal outcome for NP scope-of-practice laws; the signal-to-noise ratio will be poor, and any effects will be heavily confounded by the opioid epidemic, COVID-19, and rural hospital closures.
- **Novelty Assessment**: Low. NP scope-of-practice laws are one of the most saturated topics in health economics (studied extensively by Traczynski, Udalova, Alexander, Schnell, etc.). 
- **Top-Journal Potential**: Low. This is the textbook definition of "technically competent but not exciting." It applies a standard estimator to a saturated policy lever. Without a novel mechanism or a belief-changing pivot, it will struggle at top general-interest journals.
- **Identification Concerns**: While the DiD mechanics are fine, proving the exclusion restriction—that FPA laws drove rural mortality changes rather than concurrent rural health shocks—will be nearly impossible to defend against a skeptical referee.
- **Recommendation**: SKIP

**#4: Idea 5: State Conversion Therapy Bans and LGBTQ+ Youth Mental Health**
- **Score**: 42/100
- **Strengths**: This addresses a highly vulnerable population and a first-order welfare question with clear, direct policy relevance.
- **Concerns**: The data feasibility is fatally flawed. The YRBSS only began asking about sexual identity in 2015, but the first bans passed in 2013, meaning pre-trends for early adopters are unobservable. Furthermore, state-level YRBSS participation is spotty, and the LGBTQ+ subsample within those states is too small for reliable inference.
- **Novelty Assessment**: High in economics, though heavily studied in public health and psychology.
- **Top-Journal Potential**: Low. Top journals routinely reject papers with underpowered "nulls" that cannot rule out plausible magnitudes. The small effective *N* and missing pre-2015 data guarantee this paper will fail standard diagnostic tests.
- **Identification Concerns**: The inability to observe pre-treatment mental health trends for the LGBTQ+ subgroup before 2015 violates the core requirement of the DiD design.
- **Recommendation**: SKIP

**#5: Idea 4: State Indoor Tanning Bans for Minors and the Tanning Industry**
- **Score**: 32/100
- **Strengths**: It attempts to link a public health regulation to industry structure, which is a generally sound economic approach.
- **Concerns**: The measurement error is insurmountable. NAICS 812199 ("Other Personal Care Services") includes tattoo parlors, massage therapists, ear piercing, and diet centers. Tanning salons are a fraction of this code, meaning the dependent variable is mostly noise.
- **Novelty Assessment**: Medium. Unstudied in economics, but for good reason (data limitations).
- **Top-Journal Potential**: Low. It is a niche setting without a broader field-level takeaway. It reads as "small context, small takeaway," which the editorial appendix explicitly notes as a losing framing.
- **Identification Concerns**: The treatment (minor bans) only affects a small portion of a tanning salon's customer base, and tanning salons are only a small portion of the NAICS code being measured. The "first stage" bite will be entirely invisible.
- **Recommendation**: SKIP

### Summary

This batch contains one absolute standout (Idea 1), one salvageable idea with a good premise but flawed data architecture (Idea 3), and three ideas that suffer from either topic saturation or fatal data flaws. I strongly recommend allocating immediate resources to **Idea 1 (Right-to-Try)**, as it perfectly aligns with top-journal preferences for novel administrative data, clear causal channels, and the evaluation of unstudied policies. **Idea 3 (IVF)** is worth keeping in the pipeline only if the researchers can re-architect their data strategy to capture the 1980s/1990s pre-treatment periods.

---

## Grok 4.1 Fast

**Tokens:** 6268

### Rankings

**#1: Right-to-Try Laws and the Market for Clinical Trials**
- **Score**: 82/100
- **Strengths**: Exceptionally novel use of universe-level ClinicalTrials.gov data to test a high-stakes policy debate on clinical trial diversion, with rich mechanisms (patient substitution, sponsor reallocation), built-in placebos, and clear welfare counterfactuals (e.g., drug approval delays via VSLY). Strong identification via 38 staggered cohorts, never-treated states, 6+ pre-periods, and multiple outcome margins that fit editorial preferences for "causal chain" and "precisely bounded nulls."
- **Concerns**: Short post-periods (1-4 years) for early adopters may limit long-horizon insights prized by journals; federal law in 2018 could confound late adopters if anticipation effects are present.
- **Novelty Assessment**: Highly novel— no known causal econ papers on Right-to-Try effects (literature is purely descriptive/legal), and ClinicalTrials.gov as primary policy eval data is unprecedented.
- **Top-Journal Potential**: High. Fits winning patterns: universe admin data scales to rule out concerns empirically, mechanism decomposition + welfare deliverable (A→B→drug delay), tests industry counterstory with placebos; could pivot null to "concerns unfounded" with MDE, challenging symbolic policy wisdom.
- **Identification Concerns**: Staggered DiD robust with CS estimator and never-treated, but heterogeneous treatment effects across states (e.g., CA vs. WY trial volumes) could violate parallel trends if adoption correlates with pharma hubs; federal preemption post-2018 requires clean event-study diagnostics.
- **Recommendation**: PURSUE (conditional on: event-study pre-trends and placebo validation; MDE-powered null framing if no effects)

**#2: Nurse Practitioner Full Practice Authority and Rural Mortality**
- **Score**: 68/100
- **Strengths**: Long 30-year panel with 25+ cohorts and never-treated states enables strong parallel trends tests and long-horizon mortality effects, directly addressing rural access gaps with policy-relevant outcomes like county mortality.
- **Concerns**: Prior APEP paper on employment effects makes this incremental; broad mortality outcome risks diffuse interpretation without tight mechanism (e.g., access vs. quality).
- **Novelty Assessment**: Moderately novel—scope-of-practice effects studied (e.g., employment/utilization papers), but rural mortality angle unstudied.
- **Top-Journal Potential**: Medium. Solid first-order stakes (rural health) with long horizons, but lacks novel data/measurement or counterintuitive channel; reads as competent DiD on familiar policy without belief-changing pivot.
- **Identification Concerns**: Staggered adoption post-2010 acceleration risks heterogeneous effects; physician supply placebo good, but unobserved confounders like state Medicaid expansions could violate trends.
- **Recommendation**: CONSIDER

**#3: IVF Insurance Mandates and Women's Career Trajectories**
- **Score**: 62/100
- **Strengths**: Clever extension of fertility mandate literature to career outcomes (LFP, wages), linking to gender wage gap with dose-response via mandate stringency and strong placebos (men, older women).
- **Concerns**: Relies on aggregate ACS state-year data for nuanced trajectories, potentially underpowered for age-specific effects; small-firm exemptions complicate general equilibrium.
- **Novelty Assessment**: Moderately novel—fertility effects well-studied (Schmidt 2006+), but career deferral angle unexplored.
- **Top-Journal Potential**: Medium. Addresses gender gap puzzle, but standard DiD on saturated topic without universe data or substitution discovery; lacks tight causal chain beyond ATE.
- **Identification Concerns**: Age 25-40 as "treated" risks selection (fertility intent endogenous); staggered with long horizons ok, but mandate variation (cover vs. offer) may not be exogenous.
- **Recommendation**: CONSIDER

**#4: State Conversion Therapy Bans and LGBTQ+ Youth Mental Health**
- **Score**: 55/100
- **Strengths**: Timely policy with direct welfare stakes for vulnerable group; within-state LGBTQ+ controls strengthen design.
- **Concerns**: YRBSS data sparse (biennial, ~15-20 states, small subsamples) limits power and panel length; suicide outcomes volatile, risking underpowered nulls.
- **Novelty Assessment**: Novel—no causal studies despite 22+ adoptions—but data constraints undermine execution.
- **Top-Journal Potential**: Low. High stakes but niche + data pitfalls match "underpowered null" losses; no novel measurement or mechanism map.
- **Identification Concerns**: Limited state coverage and small N threaten DiD inference (RI sensitivity); self-reported LGBTQ+ identity in YRBSS may trend differentially pre-policy.
- **Recommendation**: SKIP

**#5: State Indoor Tanning Bans for Minors and the Tanning Industry**
- **Score**: 48/100
- **Strengths**: Connects regulation to industry/behavior; placebos (adults, non-tanning services) feasible.
- **Concerns**: NAICS not tanning-specific (signal-to-noise low); ~15-20 treated states below DiD threshold, YRBSS coverage gaps.
- **Novelty Assessment**: Novel—no econ causal evals—but too niche to compensate for flaws.
- **Top-Journal Potential**: Low. Niche outcome without scale, mechanisms, or welfare pivot; measurement issues echo "data window" losses.
- **Identification Concerns**: Few cohorts + noisy outcomes fail cluster-robust DiD; pre-trends untestable with thin data.
- **Recommendation**: SKIP

### Summary
This is a strong batch led by Idea 1, which stands out for genuine top-journal excitement via novel universe data, mechanisms, and policy bite—worth pursuing immediately. Ideas 2-3 are competent policy DiDs but lack novelty or "exciting" framing to break out; 4-5 undermined by feasibility risks and underpower. Prioritize Idea 1, pilot Idea 2 if rural health aligns with institute goals.

